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Alpha interferons at doses of3-9 MU subcutaneously, three to seven times/week, have been
administered to 32 patients with malignant endocrine pancreatic tumors. The objective
biochemical response rate was 63 percent with a median duration of 20.5 months. Significant
reduction of tumor size was only noticed in 20 percent of the patients. Alpha interferon
administered to 111 patients with malignant carcinoid tumors showed objective biochemical
responses in 42 percent of the patients with a median duration of 32 months. Another 39
percent of the patients showed stabilization of disease without any further tumor growth.
Subjective improvement was noticed in 70 percent of the patients. When survival data are
analyzed in patients with malignant carcinoid tumors, the median survival from start of
treatment was 80+ months in the group ofpatients treated with alpha interferon, which should
be compared with only eight months in a historical group treated with chemotherapy (strepto-
zotocin plus 5-fluorouracil). The adverse reactions to alpha-interferon treatment are dose-
dependent and include, mainly, flu-like symptoms, fatigue, and low-grade weight loss.
Autoimmune reactions are noted in about 20 percent of the patients. Patients treated with
recombinant alpha interferons might develop neutralizing interferon antibodies (6-27 per-
cent), which abrogate the anti-tumor response.
The anti-tumor effect in neuroendocrine tumors includes anti-proliferation, apoptosis,
differentiations, and cytotoxic/cytostatic effects. Furthermore, immunomodulation is obtained
by increased expression of class I antigens on tumor cells. Four patients also developed
antibodies directed against carcinoid tumor cells. Alpha interferons induce several nuclear
enzymes such as 2'-5'-A synthetase, p-68 kinase, and Mx-A proteins, which are involved in a
downregulation of expression ofgrowth factors, oncogenes, and peptide hormones, leading to
anti-proliferation and/or apoptosis. The response to alpha-interferon treatment might be
predicted by analysis of the induction of 2'-5'-A synthetase in samples from neuroendocrine
tumors. Stimulatory tests of hormone secretion, such as meal stimulation of pancreatic
polypeptide secretion or secretin test, clearly demonstrate a normalization during alpha-
interferon treatment, which might depend on reduced peptide production and/or secretion but
also on eradication ofmalignant cell clones.
In summary, alpha interferons have demonstrated significant anti-tumor effects in patients
with malignant neuroendocrine gut and pancreatic tumors. The adverse reactions are dose-
dependent and manageable. The anti-tumor effects of alpha interferons are pleiotropic and
include several direct effects on tumorcells but also immunomodulation.
INTRODUCTION
Neuroendocrine gut and pancreatic tumors constitute about 2 percent of all
malignant neoplasms annually diagnosed in the Western world. The incidence of
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patients with malignant tumors and the carcinoid syndrome is about 0.5 per 100,000
and with endocrine pancreatic tumors 0.4 per 100,000 [1,2]. The tumors, even in
advanced stages with metastases, demonstrate high degrees of differentiation, with
primarily diploid DNA features. Amajority ofpatients with malignant metastasizing
tumors demonstrate clinical symptoms related to hormone overproduction. These
syndromes include thecarcinoidsyndromewithflushing, diarrhea,bronchialconstric-
tion, and right heart failure due to classical mid-gut carcinoids with production of
serotonin and tachykinins. Other syndromes related to endocrine pancreatic tumors
are the Zollinger-Ellison syndrome, due to gastrin overproduction, insulinoma, or
hypoglycemic syndrome because ofinsulin/proinsulin overproduction. Otherdistinct
clinical entities are the glucagonoma syndrome, including the typical necrolytic
migratory erythemabecause ofglucagonproduction, the Verner-Morrison syndrome
because ofhigh circulating levels ofVIPgiving severe secretory diarrheawithvarious
degrees ofelectrolyte disturbances, and, finally, somatostatinoma syndromewithgall
bladder dysfunction, gallstones, steatorrea, and impaired glucose tolerance.
About one-third ofthe patients present endocrine tumors ofthe pancreaswithout
any hormone-related clinical syndromes [2], and, in addition, neuroendocrine tu-
mors of the hind-gut area also often do not present any peptide hormone-related
syndromes [3]. The hormone production by itself, with related metabolic conse-
quences, might sometimes be life-threatening, even in patients with rather small
tumors and a limited number of metastases. About one-third of patients with the
carcinoid syndrome die from a carcinoid heart disease and not from tumor growth
[1]. Therefore, even ifthe tumor itselfis advancing slowly, the hormone overproduc-
tion might be very harmful to the patient, producing a reduced quality oflife.
Because of these tumors' rarity, sometimes episodic expression, and diffuse
clinical symptoms, patients are diagnosed rather late in advanced stages of the
disease. Therefore, surgery, although the treatment ofchoice, is rarely curative, and
medical treatment is necessary. Neuroendocrine gut and pancreatic tumors have
been assigned a good prognosis, and, therefore, manyphysicians have been reluctant
to administer medical treatment in early stages of the disease. A critical look at
five-year survival rates in patients with malignant neuroendocrine tumors, however,
demonstrates survival rates that are less than 20 percent when liver metastases are
present. The median survival for patients with malignant carcinoid tumors and the
carcinoid syndrome is less than two years from diagnosis of a carcinoid syndrome
[4,5].
Medical Treatment
The medical treatment of neuroendocrine gut and pancreatic tumors includes
chemotherapy, somatostatin analogs, and interferons. Monoclonal antibodies might
be a newtherapeuticmodality inthe future. Chemotherapy hasbeen used for at least
three decades, and several single agents as well as combined treatment modalities
have been applied. So far, a combination of streptozotocin and 5-fluorouracil or
adriamycin has been the most successful, giving biochemical response rates ofabout
60 percent in patients with endocrine pancreatic tumors but only 10-30 percent in
patients with carcinoid tumors and malignant carcinoid syndrome [6-9]. Native
somatostatin has been tried since the late 1970s, but, because of its short half-life in
plasma, treatment is restricted. During the 1980s, development of somatostatin
analog made this treatment clinically feasible, and it was possible to introduce
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subcutaneous treatment with two or three administrations per day. There are studies
of both endocrine pancreatic tumors and carcinoids which have demonstrated
biochemical response rates of about 32-75 percent [10-12]. Whether the somato-
statin analog could demonstrate an anti-proliferative effect with reduction of tumor
size has been debated over the years, but there is increasing evidence that high-dose
treatment, around 3,000 p,g/day, might induce significant tumor reductions in a
number of patients with malignant neuroendocrine tumors [13]. This high-dose
treatment is currently being explored in studies in Europe and the U.S.
Interferon Therapy
Alpha interferon (IFN) was introduced by ourgroup in the treatment ofcarcinoid
tumors in 1982because ofits abilityto control hormone secretion, clinical symptoms,
and tumor growth [14]. Since then, more than 200 patients have been treated with
alpha interferons atvarious dosages, and the largest studies are summarized inTable
1 [15-25]. The largest series of patients with endocrine pancreatic tumors has been
treated at our institution (including 32patientswithvarious clinical syndromes) [23].
The dose of alpha interferon was 3-9 MU subcutaneously three to seven times per
week, with a median of 6 MU five times per week. The objective biochemical
response rate (>50 percent reduction of principal tumor markers) was 63 percent
with a median duration of 20.5 months. Significant reduction of tumor size (>50
percent reduction of the product of two perpendicular diameters) was noticed in 20
percent ofthe patients.
A significant number of patients with carcinoid tumors and malignant carcinoid
syndrome have been treatedwith alpha interferon atvarious doses (refer toTable 1).
At our own institution, alpha interferon was administered to 111 patients with
malignant carcinoid tumors and liver metastases [16]. We obtained biochemical
responses in 42 percent of the patients, with a median duration of 32 months.
Another 39 percent ofthe patients showed stabilization oftheir disease without any
further tumor growth. Sixteen percent of the patients demonstrated significant
reduction of tumor size, whereas 70 percent experienced a subjective improvement.
Survival data on our patients with malignant carcinoid tumors were analyzed. The
median survival from start of treatment was 80+ months in the group of patients
treated with alpha interferon, which is tenfold longer than that of a historical group
at our own institution, treated with chemotherapy (streptozotocin plus 5-fluoroura-
cil), reaching a median survival ofonly eight months. This historical study has still to
be evaluated in a randomized controlled study.
As indicated in Table 1, the biochemical response rates in various studies are
about 42 percent with a tumor response median of 11 percent. Moertel and
colleagues [15] administered a very high dose of recombinant interferon alpha 2a
(median, 48 MU every second day), which did not increase the response rates of
either biochemical responses or tumor responses. They could not continue with this
treatment forlongerperiods than a median ofeightweeks. In most other studies, low
to medium doses have been applied with a median ofabout 5 MU three to five times
per day, subcutaneously. The tolerance curve for alpha interferon seems to be
bell-shaped, and, therefore, it is very important to titrate individual doses for each
patient for long-term management. At our institution, we have empirically been
using the leukocyte count as an indicator of anti-proliferative effects of alpha
interferon, aiming at reducing the leukocytes below 3.0 x 109/l. Using this method,
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TABLE 2
Adverse Reactions in 111 Patients Treated with ax-IFN
% WHO Grade
"Flu-like" symptoms 89 1-2
Weight loss 59 1
Fatigue 51 1-2
Anemia ( < 110 g/l) 31 1
Leukopenia (<2.0 x 109/l) 7 1
Thrombocytopenia (100 x 109/l) 18 1
Elevated liver aminotransferases 31 1-2
Elevated blood lipids 32 1-2
Liver steatosis 19
Autoimmune reactions 20
Psoriasis (flare-ups) 3
Neutralizing IFN-abs 6-25
dosages for individual patients might range from 1.5 MU to 10 MU three to seven
times perweek, subcutaneously. Later on, we could confirm that this method clearly
correlated with the therapeutic result as well as induction of2'-5'-A synthetase (see
below). Another important observation is obtained from a study by Hanssen et al.
[18], in which they reported increased response rates after tumor reduction by
embolization ofliver metastases previous to the start ofIFN. Therefore, reduction of
tumor mass might significantly improve the therapeutic results, which also might
indicate that alpha-interferon treatment should be initiated early in the clinical
course, when the tumor mass is limited.
ADVERSE REACTIONS
The adverse reactions from alpha interferon are listed in Table 2. They include
flu-like symptoms for three to five days, initially, in almost all patients, but these
adverse events could easily be prevented by concomitant administration of
paracetamol. More severe adverse reactions are fatigue (grade I-II) in about 50
percent of the patients, low-grade weight loss in 59 percent of the patients, and
sometimes mental depression. About one-third of the patients might develop in-
creased liver enzymes, which are mainly dose-dependent, and about 20 percent of
the patients develop autoimmune reactions [26]. Patients treated with recombinant
alpha interferons might develop neutralizinginterferon antibodies invarious degrees
to different IFN preparations, which might abrogate the anti-tumor response (Table
3). In such patients, a change from recombinant interferon to human leukocyte IFN
might restore the anti-tumor effect [22].
COMBINATION TRIALS
In a recent study, we combined octreotide and alpha interferon in patients with
malignant carcinoid tumors. The design of the study was as follows: The patients
started on octreotide 50 ,ug twice a day, increasing up to 100 ,g three times daily. If
they did not respond to this dose, alpha interferon was added at a median dose of 3
MU three times per week, subcutaneously. Twenty-four patients were included in
the study; 22 patients demonstrated increased urinary 5-hydroxyindole acetic acid
(5-HIAA), and 19 patients the classical carcinoid syndrome. By using this combina-
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TABLE 3
Interferon Antibodies
No. of "Binding" Neutralizing
Preparation Patients ab (%) ab (%)a
Hu-Le-a 81 1 0
IFN-a2b 151 18 (12) 6 (4)
IFN-a2a 26 8 (31) 7 (27)
aThe antibodies neutralize the antiviral activity of a-IFN in a
bioassay.
tion, patients who were previously resistant either to octreotide alone, or to alpha
interferon alone, demonstrated biochemical responses with complete remission in
fourout of22 (18 percent) and partial remission in 13 outof22patients (59percent).
In the entire group, 77 percent of the patients experienced biochemical responses
with a median duration of 15 months [27]. None of these patients, however,
demonstrated any significant tumor reduction. When alpha interferon was with-
drawn for any reason, an immediate increase of urinary 5-HIAA as well as clinical
symptoms was noticed, and, when alpha interferon was reintroduced, a significant
amelioration wasnoted. Thesebeneficial effects ofthe combination treatmentwill be
further explored in an ongoing randomized, controlled, multi-center study in pa-
tients with malignant carcinoid tumors, where alpha interferon and octreotide are
combined from the beginning oftherapy.
MECHANISMS OF ACTION OF ALPHA INTERFERON
The anti-tumor effects of alpha interferon include anti-proliferation, apoptosis,
differentiation, andcytotoxic/cytostatic effects. Furthermore, alpha interferon clearly
demonstrates an immunomodulatory effect by increased expression of class I anti-
gens on tumor cells, development of "autoimmunity," and even carcinoid autoanti-
bodies. Alpha interferon binds to specific cell membrane receptors. Thereafter, the
signal is transduced to the cell nucleus via different pathways. An important enzyme
in this pathway is interferon-sensitive growth factor 3 (ISGF-3), which exists in a
latent form but becomes activated by alpha interferon [28]. After the signal has been
transduced to the cell nucleus, it binds to interferon-sensitive response elements
(ISREs), where it starts transcription of several interferon-inducible genes. There
exist at least 20 interferon-inducible genes, and some of them are involved in the
anti-proliferative effects ofalpha interferon. Three ofthese gene products have been
studied in our laboratory, namely 2'-5'-Asynthetase, P-68 kinase, and Mx-Aprotein.
Both 2'-5'-A synthetase and P-68 kinase induce a degradation ofmRNA forvarious
peptides, hormones, and growth factors, which results in inhibition of protein
synthesis. We have clearly demonstrated that induction of2'-5'-A synthetase in vitro
in tumor cells is correlatedwith the clinical biochemical response [29]. Most patients
who demonstrated more than a threefold increase ofbasal 2'-5'-A synthetase levels
after administration of alpha interferon clearly respond biochemically, whereas
those with lower induction were non-responders. Administration of a-IFN to pa-
tients with neuroendocrine tumors results in reduced content ofmRNA for chromo-
granin A in biopsy specimens taken from liver metastases [30]. This reduction is of
greater magnitude than a corresponding decrease in the number of tumor cells. The
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FIG. 1. Treatment of a pa-
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fact has been noticed that it takes a long time to normalize the urinary 5-HIAA in
many patients (Fig. 1) and that a complete normalization of circulating hormone
levels does not necessarily mean a complete eradication of the tumor. Even after
eight years of continuous alpha-interferon treatment with normalization of urinary
5-HIAA, there is still visible tumor remaining. This phenomenon is rather unique for
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FIG. 2. Plasma levels of neuropeptide K (NPK) during intra-arterial infusion of 10 MU of
recombinant alpha interferon into the feeding arteryofmetastasis from a patientwith carcinoid
tumor. The different curves indicate the same procedure, one year apart, showing similar
results. The hatched area indicates the reference range for the tachykinin neuropeptide K.
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biological response modifiers, and we have demonstrated that, with increasing
treatment periods, the number of tumor cells is reduced, whereas the fibrous
components of the tumor are increased [31]. These changes will not necessarily
result in any change in tumor size seen on computed tomography or ultrasound
investigations and must be followed by repeated biopsies. In the near future, the
biological activity of a tumor might be studied with positron emission tomography
(PET), where accumulation of C11-labeled hydroxytryptophan correlates with the
metabolism of the tumor. The anti-proliferative effect of a-IFN has been studied in
vivo on biopsies taken from liver metastases. By using the antibody Ki-67, a
significant reduction of immunostaining was observed after a-IFN administration,
indicating a low proliferation rate [32].
We have previously been able to demonstrate that acute infusion of alpha
interferon into the feeding artery of a carcinoid tumor causes a release within 15
minutes of neuropeptide K, one of the peptides produced by carcinoid tumors (Fig.
2). That result might be due to cytotoxic effects, in which the cell death causes a
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units of secretin in a patient with
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Minutes months' treatment with alpha in-
aecretin terferon, a complete normaliza-
75cu tion ofthis test was obtained.
release of stored peptides. A recent observation is that long-term treatments with
alpha interferon, in patients with endocrine pancreatic tumors, might normalize an
abnormal meal stimulatory test (Fig. 3) or, in patients with gastrinomas, a secretin
stimulatory test (Fig. 4). The reason for such normalization is not quite clear. One
possibility might be that malignant cell clones have been destroyed by the interferon
treatment, and thus normal endocrine pancreatic cells are left, with normal response
to these stimulatory tests.
In summary, alpha interferon has demonstrated a significant anti-tumor effect in
neuroendocrine gut and pancreatic tumors. Combination with another biological
response modifier, octreotide, seems very promising. Future studies will show the
precise role ofthis combination treatment. Adverse reactions to alpha interferon are
mostly dose-dependent, and it is important to individualize the treatment for each
patient. Today, predictive testing can be performed using induction of 2'-5'-A
synthetase. Positron emission tomography (PET) might be a future tool to follow
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these patients on IFN therapy. The treatment with alpha interferon seems to be
lifelong, and it is important to realize that the therapy is not curative, but can control
the disease for extended periods. Survival seems to be significantly prolonged during
alpha-interferon treatment, and it is accompanied by a fairlygood quality oflife.
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